GlassScriptPhysician profile
Ann S Omachi
NPI 1780743740
$6,396.32
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,319 · 2020: $1,238 · 2021: $1,564 · 2022: $773 · 2023: $444 · 2024: $58.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,359.53 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,113.93 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,084.65 | 2019-2021 | |
| Novo Nordisk INC | $542.16 | 2019-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $533.93 | 2019-2022 | |
| Pfizer INC. | $315.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $260.84 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $251.07 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.97 | 2019-2020 | |
| Esperion Therapeutics, INC. | $117.93 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $106.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $87.28 | 2019 | |
| Amarin Pharma, INC. | $75.96 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $70.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.28 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.06 | 2023-2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $27.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.42 | 2023 | |
| Amgen INC. | $25.83 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.55 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $23.49 | 2023 | Inpefa |
| Eisai INC. | $22.00 | 2021 | |
| Gilead Sciences, INC. | $21.81 | 2022 | |
| Astellas Pharma US INC | $19.35 | 2022 | |
| Medicomp INC | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Omachi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.